CytoSorbents Corp. (NASDAQ:CTSO) received a $8.00 price target from investment analysts at Maxim Group in a report released on Tuesday. The brokerage presently has a “buy” rating on the stock. Maxim Group’s price target suggests a potential upside of 52.38% from the company’s previous close.

CTSO has been the topic of several other reports. B. Riley began coverage on shares of CytoSorbents Corp. in a report on Thursday, October 6th. They issued a “buy” rating and a $11.25 price objective on the stock. Brean Capital began coverage on shares of CytoSorbents Corp. in a report on Tuesday, October 4th. They issued a “buy” rating and a $24.00 price objective on the stock. HC Wainwright restated a “buy” rating on shares of CytoSorbents Corp. in a report on Tuesday, November 8th. Finally, Aegis began coverage on shares of CytoSorbents Corp. in a report on Wednesday, October 26th. They issued a “buy” rating and a $20.00 price objective on the stock. Five equities research analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average target price of $15.05.

Analyst Recommendations for CytoSorbents Corp. (NASDAQ:CTSO)

Shares of CytoSorbents Corp. (NASDAQ:CTSO) opened at 5.25 on Tuesday. The firm has a 50-day moving average of $5.57 and a 200 day moving average of $5.09. The firm’s market capitalization is $133.71 million. CytoSorbents Corp. has a 52 week low of $3.11 and a 52 week high of $7.48.

A number of large investors have recently made changes to their positions in CTSO. Citadel Advisors LLC acquired a new stake in shares of CytoSorbents Corp. during the third quarter valued at $106,000. BlackRock Institutional Trust Company N.A. increased its stake in shares of CytoSorbents Corp. by 13.2% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 29,955 shares of the company’s stock valued at $192,000 after buying an additional 3,495 shares during the last quarter. Finally, Advisor Group Inc. increased its stake in shares of CytoSorbents Corp. by 1.1% in the third quarter. Advisor Group Inc. now owns 305,145 shares of the company’s stock valued at $1,953,000 after buying an additional 3,300 shares during the last quarter. 6.85% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This article was first reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this article on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be read at https://www.thecerbatgem.com/2016/11/24/cytosorbents-corp-ctso-pt-set-at-8-00-by-maxim-group.html.

CytoSorbents Corp. Company Profile

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.

5 Day Chart for NASDAQ:CTSO

Receive News & Stock Ratings for CytoSorbents Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoSorbents Corp. and related stocks with our FREE daily email newsletter.